1
|
Takeuchi J, Ozaki I, Hata K, Nozawa M, Fukushima K, Fukumori N, Imanaka M, Sakanishi Y, Shima M, Morimoto T. Mumps vaccination and immune status among Japanese university students: A multicenter cross-sectional study. J Public Health Res 2024; 13:22799036241246702. [PMID: 38694450 PMCID: PMC11062233 DOI: 10.1177/22799036241246702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 03/26/2024] [Indexed: 05/04/2024] Open
Abstract
Background During the mumps outbreak in Japan in 2016, 159,031 cases were reported. In a survey conducted in 2015, mumps vaccination rates for the first dose were 30%-40%. However, the rates for two or more doses were not determined. We assessed the mumps vaccination rates and mumps infection prevalence according to vaccine doses received. Design and methods This was a multicenter cross-sectional study. Students from three universities participated in 2019. Informed consent was obtained from the students and their guardians. The primary outcome was the prevalence of breakthrough mumps infection according to the number of doses of vaccine received. We collected data on past illnesses of vaccine-preventable diseases and vaccination history using a questionnaire, photocopies of the Maternal and Child Health Handbook from the guardians, and virus antibody titers from the universities' health centers. Results This study assessed 2004 eligible students and included 593 (29.6%); of these, 250 (42.7%) had a mumps infection history. Furthermore, 264 (44.6%), 31 (5.2%), and 2 (0.3%) students received the first, second, and third doses of mumps vaccine, respectively. The mumps seropositivity prevalence was 43.2% (n = 127), 36.7% (n = 97), 26.7% (n = 8), and 100% (n = 2) for the no-, first-, second-, and third-dose groups, respectively (p for trend = 0.09). The mumps infection prevalence rates were 69.8% (n = 203), 11.3% (n = 28), 3.9% (n = 1), and 0% for the no-, first-, second-, and third-dose groups, respectively. Conclusions Approximately 1 in 10 students who had received only one dose of mumps-containing vaccine had a breakthrough infection history.
Collapse
Affiliation(s)
- Jiro Takeuchi
- Institute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan
| | - Iwata Ozaki
- Health Administration Center, Saga Medical School Faculty of Medicine, Saga University, Saga, Japan
| | - Kokichi Hata
- Health Service, The University of Shimane, Izumo, Japan
| | - Manami Nozawa
- Health Center, Hyogo Medical University, Nishinomiya, Japan
| | | | - Norio Fukumori
- Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Mie Imanaka
- Nursing and Dietetics Department, The University of Shimane, Izumo, Japan
| | - Yuta Sakanishi
- Sakanishi Internal Medicine and Pediatrics Clinic, Omuta, Japan
| | - Masayuki Shima
- Department of Public Health, Hyogo Medical University, Nishinomiya, Japan
| | - Takeshi Morimoto
- Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan
| |
Collapse
|
2
|
Sakanishi Y, Takeuchi J, Suganaga R, Nakayama K, Nishioka Y, Chiba H, Kishi T, Machino A, Mastumura M, Okada T, Suzuki T. Association between administration or recommendation of the human papillomavirus vaccine and primary care physicians' knowledge about vaccination during proactive recommendation suspension: a nationwide cross-sectional study in Japan. BMJ Open 2023; 13:e074305. [PMID: 37993154 PMCID: PMC10668282 DOI: 10.1136/bmjopen-2023-074305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 11/07/2023] [Indexed: 11/24/2023] Open
Abstract
OBJECTIVE The Japanese government suspended the proactive recommendation of the human papillomavirus vaccine (HPVv) in 2013, and the vaccination rate of HPVv declined to <1% during 2014-2015. Previous studies have shown that the recommendation by a physician affects a recipient's decision to receive a vaccine, and physicians' accurate knowledge about vaccination is important to increase vaccine administration. This study aimed to evaluate the association between physicians' knowledge of vaccination and the administration or recommendation of HPVv by primary care physicians (PCPs) in the absence of proactive recommendations from the Japanese government. DESIGN Cross-sectional study analysed data obtained through a web-based, self-administered questionnaire survey. SETTING The questionnaire was distributed to Japan Primary Care Association (JPCA) members. PARTICIPANTS JPCA members who were physicians and on the official JPCA mailing list (n=5395) were included. PRIMARY AND SECONDARY OUTCOME MEASURES The primary and secondary outcomes were the administration and recommendation of HPVv, respectively, by PCPs. The association between PCPs' knowledge regarding vaccination and each outcome was determined based on their background and vaccination quiz scores and a logistic regression analysis to estimate the adjusted ORs (AORs). RESULTS We received responses from 1084 PCPs and included 981 of them in the analysis. PCPs with a higher score on the vaccination quiz were significantly more likely to administer the HPVv for routine and voluntary vaccination (AOR 2.28, 95% CI 1.58 to 3.28; AOR 2.71, 95% CI 1.81 to 4.04, respectively) and recommend the HPVv for routine and voluntary vaccination than PCPs with a lower score (AOR 2.17, 95% CI 1.62 to 2.92; AOR 1.88, 95% CI 1.32 to 2.67, respectively). CONCLUSIONS These results suggest that providing accurate knowledge regarding vaccination to PCPs may improve their administration and recommendation of HPVv, even in the absence of active government recommendations.
Collapse
Affiliation(s)
- Yuta Sakanishi
- Sakanishi Internal Medicine and Pediatrics Clinic, Omuta, Fukuoka, Japan
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
| | - Jiro Takeuchi
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Institute for Clinical and Translational Science, Nara Medical University, Kashihara, Nara, Japan
| | - Rei Suganaga
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Tessyoukai Kameda Family Clinic Tateyama, Tateyama, Japan
| | - Kuniko Nakayama
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- My family Clinic Gamagori, Gamagori, Japan
| | - Yosuke Nishioka
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Nishioka Memorial Central Clinic, Shima, Japan
| | - Hiroshi Chiba
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Family Medical Practice Hanoi, Hanoi, Viet Nam
| | - Tomomi Kishi
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Japan Baptist Hospital, Kyoto, Japan
| | | | - Mami Mastumura
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Department of Preventive Services, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tadao Okada
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Tessyoukai Kameda Family Clinic Tateyama, Tateyama, Japan
| | - Tomio Suzuki
- Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan
- Department of General Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| |
Collapse
|